![微環(huán)載體介導(dǎo)肝再生增強(qiáng)因子的肝纖維化的治療_第1頁](http://file2.renrendoc.com/fileroot_temp3/2021-11/24/2aa50f11-fad3-4e99-9ead-6456d03bc0f0/2aa50f11-fad3-4e99-9ead-6456d03bc0f01.gif)
![微環(huán)載體介導(dǎo)肝再生增強(qiáng)因子的肝纖維化的治療_第2頁](http://file2.renrendoc.com/fileroot_temp3/2021-11/24/2aa50f11-fad3-4e99-9ead-6456d03bc0f0/2aa50f11-fad3-4e99-9ead-6456d03bc0f02.gif)
![微環(huán)載體介導(dǎo)肝再生增強(qiáng)因子的肝纖維化的治療_第3頁](http://file2.renrendoc.com/fileroot_temp3/2021-11/24/2aa50f11-fad3-4e99-9ead-6456d03bc0f0/2aa50f11-fad3-4e99-9ead-6456d03bc0f03.gif)
![微環(huán)載體介導(dǎo)肝再生增強(qiáng)因子的肝纖維化的治療_第4頁](http://file2.renrendoc.com/fileroot_temp3/2021-11/24/2aa50f11-fad3-4e99-9ead-6456d03bc0f0/2aa50f11-fad3-4e99-9ead-6456d03bc0f04.gif)
![微環(huán)載體介導(dǎo)肝再生增強(qiáng)因子的肝纖維化的治療_第5頁](http://file2.renrendoc.com/fileroot_temp3/2021-11/24/2aa50f11-fad3-4e99-9ead-6456d03bc0f0/2aa50f11-fad3-4e99-9ead-6456d03bc0f05.gif)
版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡介
1、微環(huán)載體介導(dǎo)肝再生增強(qiáng)因子的肝纖維化的治療researcharticlesaugme nterofliverrege nerati ongen etherapyusi nganovelminicirclednavectoralleviateslive rfibrosisinrats1,221,21,223xinwu,guangzeliu,maomu,yuti ngpe ngxiumeili 丄 iside ng,221,*andxia ngpingkon g2?*zhe nweizha ngmeijua nchens on gyou,instituteoflifescie ncea ndbio
2、 pharmaceuticsshenyangpharmaceuticalu niversit y,she ny ang,china;2keylaboratoryofliverdiseasezcentreoflnfectiousdiseases,458thhospitalofpla,guangzhou,china;3thefifthaf ?liatedhospital,s un yat-se nun iversity,zhuhai,chi na.1liver?brosisresultsi ncirrhosis,liverca ncera ndliverfailur 巳 whichisamajor
3、causeof mortalityworldwide.ge netherapyisarelatively newparadigminmedicinewithen ormoustherapeuticpote ntial.thedevelopme ntofa nef?cie ntan dsafedeliverysyst emisesse ntialforcli nicalge netherapy.lnthepresentstudyweevaluatedaugmenter ofliverrege neratio n/growthfactorervllike(alr/gfer)gen ethera p
4、euticeffect mediatedbya no velminicirclevector(mc-halr).theresultsinliver?broticratsthatr eceivedmc-halrthroughhydrod yn amics-basedtra nsfection(hbt)for8weeksindi catedthattheminicirclednavectorproducedamoreeffectivege netherapyeffectth an traditio nalplasmids(pcdna3.1halr).eve nwhe nwereducedthetr
5、eatmentdos eofmc-halrto30%(w/w)a ndthetreatme ntfreque ncyfromweeklytobiweekly,th einvitroa ndinvivoresultsstilldemonstratedthathigheralrge neexpressio nsigni? cantlyblockedincreasesi ntransforminggrowthfactorbl(tgfbl),plateletderived growthfactor-bb(pdgf-bb)/anda-smoothmuscleaorta(a-sma)levels;effe
6、ctively suppressedtheproductio no fcollage nsespeciallycollage nl;andeffectivelyalleviat edliverinjurya nd?brosisi nratsherebyimprovi ngthesurvivalrateofliver?broticrat s.ltispreliminarilyc oncl udedthattherelativeoverexpressionofmchalrinhibitsth eactivati ono fhepaticstellatecells(hscs),therebyalle
7、viati ngliver?brosisinrats keywords:minicirclednavector,high-levelexpression,augm en terofliverrege nera tion(alr),ge netherapy川 ver?brosis,hydrod yn amics-basedtra nsfection(hbt)introductionliverfibrosisresultsfromchronicdamagetotheliverinconjunctionwiththeex cessiveaccumulati ono fextracellularmat
8、rix(ecm)proteins,whichisacharacteristic ofchronicliverdiseasescausedbyviralautoimmunedrug-relatedholestaticorm etabolicdiseases.advancedliver?brosisresultsincirrhosisjiverca ncer;andliverfail ure,whichisamajorcauseofmortalityworldwide.lgen etherapyisarelativel yn ewparadigminmedicine,withe normousth
9、erapeuticp ote ntial.a ndliver-targetedge nedeliveryhasattractedagreatdealofatte ntion.21 na dditio ntowellk no wngrowthfactorszsuchashepatocytegrowthfactor(hgf)a ndep idermalgrowthfactor(egf),aug-menterofliverrege neration(alr),alsok nown asgr owthfactorervl-like(gfer),isanothercyto-kin eofvitalimp
10、orta ncetoliver3,4alrisamemberofthe newlydiscoveredalr/erv lproteinfamilywithfad-linkedsulfhydryloxidaseactivitythatcatalyzesdisul?debo n dformatio n.5,6thecxxcmotifofalrisesse ntialforcellsurvival7a ndthebioge nesi sofcytosolicfe/sproteins.8ln-deed?alrhasbee ndem on stratedtofunctio nasasur vivalfa
11、ctorforhepatocytes,a ndthedepleti ono falrproteinbya ntise nseolig onucle otidesleadstohepatocytecelldeath.7alrpromotesthegrowthofhepatocytesinth eregeneratingorinjuredliver,3,7playsapivotalroleasanimmunoregulatora ndasa n enzymeactivator,9?10andprotectshepatocytesagainstapoptosis.4furthermore,v ari
12、ousreportsi ndicatethatalrappearstobea no velimporta ntcytokinewithpote nti alcli nicalsig ni?cancei nthege netherapyofliver?brosis.!x12*corresponde nce:prof.s on gyoujnstituteoflifescie ncea ndbio pharmaceutics,s henyangpharmaceuticaluniversitno.loswenhuaroadjlooieshenyanghi n a.e-mail:yous on g206
13、;orprof.xiangpingk on g,keylaboratoryofliverdi seasezcentreofl nfectiousdiseases,458thhospitalofpla,gua ngzhou,chinaemaii:xia ngping_k on g880jhumangenetherapwlume27numberlla2016bymarya rmliebertjnc.d0l:10.1089/hum.2016.006 minicircle-mediatedalrgenetherapy881nevertheless,o neofthemajorbarrierstoalr
14、ge netherapyisthesafetya ndef?ci enc yofthevectorsusedforge netra nsferi neukaryoticcells.comparedwithviralvectors, non viralvectorsaresafeandsimpletopreparea ndmodify.l3plasmiddnaisfreque n tlyusedfor non viralge netherapy,butthepresen ceofcpgmotifsa ndtheiras-sociat edsequencesi nbacterialdnacause
15、sanimm uno toxicresponseafterthedeliveryoft heseplasmidvectorstomammalia nhosts,whichisapote ntialriskforsafecli nicalapp licatio nsan dreducestra nsgeneexpressio n.l4moreover;theresultsofourprevious experime ntdemo nstratedlowlevela ndshorttermexpressio ninresp on setoplas mid mediatedalrge nethera
16、pyi nrats,withlargei ndividualdifferences(unpublish edj.there-forethedevelopmentofa nef?cie ntan dsafedeliverysystemisessentialf oralrge netherapyminicircles(ivics),novelplasmiclbasedvectorsthatarecompo sedsolelyofeukaryoticsequencesd ono tcarryeitherantibioticresista ncege nesorb acterialorigi nsof
17、replicati on ;thus,mcsi nducemarkedlyreducedimmu nean din?a mmatoryresp on sesandeffectivelyprotecttransgeneexpressio nfrombeingsile nee dbecauseoftheprese nceofbacterialbackb on ese q uences15theuseofmcsisa nin terestingap-proachtoi ncreasethesafetya ndef?ci en cyofplasmid basedvectorsfor clinicalg
18、e netherapy.16therefore,i nthepresentstudy,a nalrexpressi on cassettei naminicirclednavector waspre-paredforthe?rsttime,theexpressi on levelofthealrge nemediatedbyami n icirclednavectorwascomparedwiththatofc onven tionalplasmidsbothinvitroa ndi n vivoa ndthe8weekge netherapyeffectin?broticratswascom
19、pared.materialsandmethodspare ntalplasmidc on structio nthehuma nalrgeneexpressi onf ragmentcontainingacmvpromoter,huma nalrc odin gseque nce(ge nban kaccessi onnu mber:nm_005262)?a ndbghpolyade nylati onsignalsequencewaspcr-ampli?edwithaforwardprimer(5 c -gactgaagatctatgtacgggccagatata-3 c )?revers
20、eprimer(5 c -ataccgctcgagggttctttccgcctcagga-3 c )zandprimestarmaxdnapoly-m erase(takara),usingthepreviouslyc on structedpcdna3.1-halr12asatemplate.th eampli?edfragme ntswereexcisedwithbgllla ndxhol(neb)a ndthe nligatedbetwee nattbandattpsites(fig.la,parentalplasmid).plasmidpreparatio napreviouslyre
21、portedprotocoll7forminicirclednavectorproductio nwasusedwit hsomemod-i?cations.brie?y,escherichiacolistrainzy-cy10p3s2t(akindgiftfromdr.zhiyingch en ,sta nforduniversity)wastra nsformedwiththepare ntalplasmids. on etra nsform an twaspickeda ndgrow no ver night(od6004.5-5.0)i n5mltbbroth(ln vitroge n
22、)con tainin gka namyci n( 50lg/ml)at37°cwithshaki ngat250rpn%followedbyampli?catio n with0.1-0.3%oftheinoculumintbbrothc on tainingka namycin(50lg/ml)for:15hr then,aftertheadditio no fal.2-foldvolumeoflbbroth(l nvitroge n)con taining0.03% l-arabi no se(sigma-aldrich)a nd3%lnnaoh,thei ncubati on wasc ontinu edfora nad ditional6hrat32°cwithshakingat250rpm.e.colistrai ndh5a(l nvitrogen)wastransformedwithpcdna3.1halr.onetransfo rmantcolonywaspickedandgrow no vernight(od6004.5-5.0)i n5mllbbroth(l nvitr oge
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。
最新文檔
- 2024-2025學(xué)年重慶市渝中區(qū)四年級(jí)(上)期末數(shù)學(xué)試卷
- 2022-2023學(xué)年福建省廈門市集美區(qū)雙塔小學(xué)片區(qū)四年級(jí)(上)期末數(shù)學(xué)試卷
- 河北工業(yè)大學(xué)土木工程測(cè)量試題及答案-
- 2025年個(gè)人房屋拆除合同標(biāo)準(zhǔn)樣本(2篇)
- 2025年企業(yè)前臺(tái)臨時(shí)用工協(xié)議范文(2篇)
- 2025年買方信貸融資意向性協(xié)議參考樣本(三篇)
- 2025年人防土建工程合同(2篇)
- 2025年個(gè)人貸款合同標(biāo)準(zhǔn)范文(2篇)
- 專題02 利用導(dǎo)函數(shù)研究函數(shù)的單調(diào)性問題(常規(guī)問題)(典型題型歸類訓(xùn)練) 解析版
- 休閑娛樂場所油漆裝修協(xié)議
- 北師大版八上《生物的遺傳和變異》
- 交叉口同向可變車道動(dòng)態(tài)控制與信號(hào)配時(shí)優(yōu)化研究
- 護(hù)理專業(yè)應(yīng)聘個(gè)人簡歷
- 北師大版二年級(jí)上冊(cè)100以內(nèi)加減法豎式計(jì)算題300道及答案
- 安華農(nóng)業(yè)保險(xiǎn)股份有限公司北京市地方財(cái)政生豬價(jià)格指數(shù)保險(xiǎn)條款(風(fēng)險(xiǎn)敏感型)
- 事業(yè)單位考試題庫:公文寫作能力測(cè)試試題及答案
- 2024-2025學(xué)年北師大版初一物理上冊(cè)期末質(zhì)量檢查卷及答案
- 6.2《青紗帳-甘蔗林》-【中職專用】高一語文課件(高教版2023·基礎(chǔ)模塊下冊(cè))
- 2023年開工第一課及復(fù)工復(fù)產(chǎn)考試試題(含答案)
- 宗教知識(shí)的課件
- GB/T 22849-2024針織T恤衫
評(píng)論
0/150
提交評(píng)論